Antibody

APP or β-Amyloid (6E10)

Tools

Back to the Top

Clonality: monoclonal
Host: Mouse
Isotype: IgG1
Methods: ELISA, IH, IP, WB
Source: Covance Research Products, Inc.
Cat# SIG-39300
References:
(Gandy, 2010
Kallhoff, 2007
Dreses-Werringloer, 2008
Tampellini, 2007
Schmidt, 2007
Ostrowski, 2007,
all, unspecified formulation)
Formulation: crude ascites
Reactivity:
Reacts in: Human

Immunogen/Epitope

epitope lies within amino acids 3-8 of beta amyloid (EFRHDS)

Specificity

reactive to aa 1-16 Aβ and to APP, reacts to the abnormally processed isoforms, as well as precursor forms

Comments / Questions

Make a comment or submit a question

To make a comment you must login or register.

Comments on this content

No Available Comments

References

Paper Citations

  1. . Days to criterion as an indicator of toxicity associated with human Alzheimer amyloid-beta oligomers. Ann Neurol. 2010 Aug;68(2):220-30. PubMed.
  2. . Lack of alpha-synuclein increases amyloid plaque accumulation in a transgenic mouse model of Alzheimer's disease. Mol Neurodegener. 2007;2:6. PubMed.
  3. . A polymorphism in CALHM1 influences Ca2+ homeostasis, Abeta levels, and Alzheimer's disease risk. Cell. 2008 Jun 27;133(7):1149-61. PubMed.
  4. . Internalized antibodies to the Abeta domain of APP reduce neuronal Abeta and protect against synaptic alterations. J Biol Chem. 2007 Jun 29;282(26):18895-906. PubMed.
  5. . SorLA/LR11 regulates processing of amyloid precursor protein via interaction with adaptors GGA and PACS-1. J Biol Chem. 2007 Nov 9;282(45):32956-64. PubMed.
  6. . Statins reduce amyloid-beta production through inhibition of protein isoprenylation. J Biol Chem. 2007 Sep 14;282(37):26832-44. PubMed.

Further Reading

News

  1. Phoenix: Vision of Shared Prevention Trials Lures Pharma to Table
  2. Phoenix: Can Alzheimer’s Prevention Initiative Break a Catch-22?